Home
Search results “Diovan medication and vascular growth”
Pharmacology - HYPERTENSION & ANTIHYPERTENSIVES (MADE EASY)
 
15:07
Support us on Patreon: https://www.patreon.com/speedpharmacology Follow us on Facebook: https://www.facebook.com/SpeedPharmacology/ Get Speed Pharmacology Merch Here: https://teespring.com/stores/speed-pharmacology **************************************************************************************************** Topics covered include: basic pathophysiology of hypertension, regulation of blood pressure, cardiac output, systemic vascular resistance, baroreceptors, alpha & beta receptors, vasoconstriction, vasodilation, renin-angiotensin-aldosterone system, bradykinin, nitric oxide. Mechanism of action of antihypertensive drugs and their side effects; adrenergic antagonists; alpha & beta blockers, centrally acting adrenergic agents, dihydropyridine & nondihydropyridine calcium channel blockers, loop, thiazide, potassium-sparing diuretics, renin inhibitors, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor type 1 blockers (ARBs), endothelin receptor antagonist, dopamine-1 receptor agonist, peripheral vasodilators. Drugs mentioned include; Doxazosin, Prazosin, Clonidine, Methyldopa, Amlodipine, Felodipine, Nicardipine, Nifedipine, Diltiazem, Verapamil, Furosemide, Hydrochlorothiazide, Triamterene, Spironolactone, Aliskiren, Benazepril, Captopril, Enalapril, Lisinopril, Quinapril, Ramipril, Candesartan, Irbesartan, Losartan, Olmesartan, Valsartan, Bosentan, Fenoldopam, Sodium Nitroprusside, Nitroglycerin, Hydralazine, and Minoxidil.
Views: 241093 Speed Pharmacology
New Drug Could Reduce Cardiovascular Deaths
 
01:08
The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Follow Madison Burke: http://www.twitter.com/MBurkeNews See more at http://www.newsy.com Sources: Wikimedia Commons http://commons.wikimedia.org/wiki/File:Heart%27s_Ubication.jpg Novartis http://www.novartis.com/newsroom/media-releases/en/2014/1847958.shtml American Heart Association http://newsroom.heart.org/album?p=15&s=title&page=3&id=4ffd6ceb29371a77a900002c&t=photo The Wall Street Journal http://online.wsj.com/articles/glaxos-chief-faces-rising-pressure-1407791749 Industries News Press http://imarketreports.com/novartis-study-shows-new-drug-cuts-cardiovascular-death-rate.html Businessweek http://www.businessweek.com/news/2014-08-30/novartis-heart-failure-drug-tops-standard-in-study Image via: GustavoHCL / CC BY SA 3.0 http://commons.wikimedia.org/wiki/File:Heart%27s_Ubication.jpg
Views: 1702 Newsy Science
Biomarkers in Heart Failure: How to Guide Clinicians
 
50:26
Version with interactive Table of Contents is here: https://goo.gl/wJgpbO Presenter: Alan S. Maisel (US) About the presenter: Alan S. Maisel is a Professor of Medicine at the University of California, San Diego (UCSD). He is the Director of the Coronary Care Unit and Heart Failure Program at the VA San Diego Healthcare System in La Jolla, California. Dr. Maisel is active on the faculty at UCSD where he has won numerous teaching awards. He just completed a ten-year stint as Associate Editor of the Journal of the American College Cardiology.Dr Maisel is considered one of the world’s experts on cardiac biomarkers and has over 400 scientific publications. He has authored several ground-breaking manuscripts that have paved the way for development of diagnostic tools for patients with congestive heart failure. In particular, he was the leading investigator on studies that brought the use of BNP into clinical practice. He has been lead investigator on seven multicentre biomarker trials.He is now working non-stop to delineate the clinical role of sST2 levels in clinical practice and in guiding therapy. Moderators: Evgenija Homsak (SL) - Kari Pulkki (FI) Abstract: Biomarkers that are surrogates for cardiac pathophysiology may help us understand the "state of the heart" in heart failure and may be indications for certain treatments. A good biomarker will also be able to be monitored and a change in the level will reflect a change in the condition. I will speak of three biomarkers that do exactly this (natriuretic peptides, high sensitivity troponins and sST2). Natriuretic peptides (NPs) (BNP and NTproBNP) are guideline standards to confirm the diagnosis of heart failure. They are good for monitoring volume as we diurese the patient. Their weaknesses include wide variability in levels in a given patient as well as elevations not secondary to an increase in left sided filling pressures. Additionally, their value is questionable in patients receiving Entresto (a drug that inhibits breakdown of NPs). High sensitivity troponin in the setting of acute heart failure (and maybe chronic) represents subendocardial necrosis and has a bad prognosis. It is possible that drugs like nitrates will be used in heart failure treatment more commonly when levels of high sensitivity troponin are high. Finally, sST2 is a marker of fibrosis and is elevated in virtually all patients with heart failure. In the acute setting, it defines a "sicker" patient who needs advanced treatment to avoid re-hospitalization. In the chronic setting, titrating medication to a sST2 level below 35 ng/ml appears to mitigate risk, even in the setting of a continued high NP level. Data with Entresto suggest sST2 levels are going to be useful in both selection of patients for Entresto as well as monitoring treatment and maybe regulating the dose. Recorded at November 17 2016.
Views: 2292 EFLM
The Role of Angiotensin II in the Process of Atherosclerosis
 
03:45
This animation reviews the physiological effects of Angiotensin II in the cardiovascular system that contribute to the development of atherosclerosis.
Views: 17875 Mechanisms in Medicine
NAGOYA HEART Study
 
03:39
Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance
Lixiana
 
00:02
Decasegui estagiária
Novel developments in the treatment of chronic heart failure - Prof Andrew Coats
 
02:49
Andrew Coats, Professor, Researcher & Cardiologist, and Director of the Monash-Warwick Alliance Strategy, Monash University of Melbourne, Australia, speaks to Cardio Debate about novel developments for the treatment of chronic heart failure. For more interviews like this please visit www.cardio-debate.com TRANSCRIPT What was your talk about today at the International Workshop on Treatment of Cardiovascular Disease in 2016? In my talk today I covered the development for heart failure treatments, what has changed since the last European Guidelines that were in 2012, while we wait for the new guidelines at the end of this month. We highlighted changes in drug treatment, particularly two new trials that have come out – the PARADIGM-HF and the ATMOSPHERE study. And in addition, what’s on the horizon for new devices. Which are the main developments to highlight regarding new developments and challenges in the management of patients with heart failure? So the two most important trials have come out, and those are ATMOSPHERE, which is the renin-inhibitor that showed no advantage of using a renin-inhibitor either as an alternative to an ACE-inhibitor or an addition. So I think it shows that renin inhibition doesn’t seem to add a lot in the treatment of chronic heart failure. In contrast, PARADIGM-HF looked at the combination of valsartan with a neutral endopeptidase inhibitor in the drug that was called LCZ696 – now called sacubitril/valsartan – that showed a substantial superiority over enalapril, the ACE inhibitor. So the question now is how do we implement those changes in practice? How many of the patients that see a heart failure cardiologist or general physician are suitable for the swap-over to the new drug? According to the results of the trial, could the new treatment be extended to more patients? PARADIGM-HF was a very important trial. It showed that sacubitril/valsartan was superior to enalapril. The issue is how widely can we apply that in practice? Because the trial was the first of it’s kind with that particular combination pill agent, and as a result we only have that trial to go by. The question is, the patients in that trial were very highly selected. They had to have established heart failure, they had to have elevated nateuretic peptides, but they had to have already tolerated relatively high doses of ACE inhibitor and the trial medication. So when we have patients who aren’t on high dose ACE-inhibitor or haven’t tolerated that, we really don’t know whether the drug would be as superior in that patient population. So in my own belief, I think we need another trial to answer that question in a broader patient population.
Views: 176 Cardio Debate
Major Development in Antihypertensive Therapeutics Market by 2020
 
00:31
The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017. Scope The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the hypertension in the major developed markets.The report includes - • Disease overview, as well as treatment algorithms and treatment use patterns • Market size and forecast for the hypertension market from 2013-2020 • Major marketed products for hypertension along with a heat map of product performance • In-depth pipeline analysis for global pipeline in hypertension along with clinical trial failure rate analysis • Key drivers and restraints that have had and are expected to have a significant impact upon the market • Key licensing and co-development agreements that could have impact on growth trends Complete report is available @ http://www.reportsnreports.com/reports/287910-antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries.html .
Views: 535 Nancy Freedman
ESC 2014 Hotline I Cardiovascular Disease Novel Therapies
 
14:59
Elliott Antman, MD, FAHA, Mariell Jessup, MD, FAHA, and Mark Creager MD, FAHA discuss the science that was presented during Hotline I Cardiovascular Disease Novel Therapies at ESC 2014 in Barcelona, including PARADIGM HF, CONFIRM, MORE-CRT, COPPS-2.
Views: 542 AHAScienceNews
FDA Warns Manufacturers Linked to Superbugs
 
01:05
http://www.dailyrxnews.com/olympus-corp-pentax-medical-and-fujifilm-holding-corp-notice-fda-cleaning-sterilization-violations The US Food and Drug Administration (FDA) has issued warning letters to Olympus Corp, Pentax Medical and Fujifilm Holdings Corp, citing multiple violations related to medical devices. "The FDA takes these violations very seriously and will continue to monitor these firms to ensure they take appropriate corrective action," the FDA explained in a statement. "However, currently available information indicates that the benefits of these devices continue to outweigh the risks in appropriately selected patients." In other words, each company will continue to operate amid the newfound concerns. Those concerns simply need to be addressed in short order if Fujifilm and Pentax are to avoid further consequences. According to Reuters, noteworthy violations were related to cleaning, sterilization, testing and marketing of medical equipment. There's particular anxiety surrounding devices known as duodenoscopes, reusable instruments used to diagnose and treat conditions via a pathway down the patient's throat. Such procedures are common in the US, but there's some risk that the devices may sometimes transmit antimicrobial-resistant bacteria — a risk the FDA cited as early as 2009. Reuters reports that duodenoscopes have been linked to such "superbug outbreaks" at several hospitals around the country. One such outbreak recently occurred at Ronald Reagan UCLA Medical Center, where seven patients contracted carbapenem-resistant Enterobacteriaceae (CRE). CNN reported in March that duodenoscopes produced by Olympus were used on the patients during routine endoscopic procedures — and that the device in question had never been formally approved by the FDA. "Can you imagine a prescription drug getting out on the market that didn't go through the approval process?" said Dr. Steven Nissen, chief of cardiovascular medicine at the Cleveland Clinic, per CNN. "Devices need to be regulated more vigorously. This is really disturbing." The World Health Organization (WHO) breaks down the potential threat of so-called superbugs, explaining that, "Resistant microorganisms (including bacteria, fungi, viruses and parasites) are able to withstand attack by antimicrobial drugs, such as antibacterial drugs (e.g. antibiotics), antifungals, anitvirals, and antimalarials, so that standard treatments become ineffective and infections persist, increasing the risk of spread to others."
Views: 31 dailyRx
Diuretics, β-blockers, and statins in increasing the risk of diabetes
 
05:47
Read the full article online: http://www.bmj.com/content/347/bmj.f6745 The use of β blockers, diuretics, and statins has been established to reduce cardiovascular morbidity and mortality in a variety of diseases.However, although statins reduce cardiovascular events and mortality in patients with coronary artery disease or equivalent risk factors, debate continues about their role in primary prevention in lower risk populations. Despite the overwhelming benefits of these drugs on cardiovascular outcomes, recent evidence suggests that long term use may increase the risk of diabetes. Large trials examining cardiovascular outcomes and mortalities suggested an increased incidence of new onset diabetes with long term use of diuretics. Likewise, other studies have reported an increased incidence of diabetes in people treated with statins, prompting the US Food and Drug Administration to release a safety label change in 2012. Furthermore, β blockers have been implicated in impaired glucose metabolism, especially with diuretics. Large scale studies with serial glucose measurements examining the association between these drugs and new onset diabetes in patients with impaired glucose tolerance are limited. We reanalysed data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study to examine the relation between risk of new onset diabetes and use of β blockers, thiazide diuretics, or statins in treatment naïve patients. In this study, the researchers set out to examine the degree to which use of β blockers, statins, and diuretics in patients with impaired glucose tolerance and other cardiovascular risk factors is associated with new onset diabetes.
Views: 1307 The BMJ
3 đột phá giúp đẩy lùi bệnh tim mạch
 
06:30
3 đột phá giúp đẩy lùi bệnh tim mạch. Cùng với những tiến bộ về khoa học, kỹ thuật, những đột phá về thuốc trị bệnh tim mạch không chỉ kéo dài thêm sự sống, mà nó còn là những bước đột phá quan trọng trong ngành y. 1. Khám phá protein điều hòa cholesterol. 2. Thuốc làm loãng máu ngăn ngừa đột quỵ. 3. Sự kết hợp đột phá mới trong điều trị suy tim. Chi tiết nội dung bài viết và video này xem tại: http://www.mangyte.vn/news-3-dot-pha-giup-day-lui-benh-tim-mach-39733.html Subscribe đăng ký kênh để đón xem những video mới nhất tại: https://goo.gl/lLPj0C Facebook Mạng Y Tế: https://goo.gl/dWQRyO Android App Mạng Y Tế: https://goo.gl/7hmU7R Website Mạng Y Tế: https://goo.gl/F7mr6H Google +: https://goo.gl/cgy4Sv Vidme Mạng Y Tế: https://goo.gl/p1JmdV SoundCloud Mạng Y Tế: https://goo.gl/qKyVFJ TopBuzz: https://goo.gl/5RWpRW Các VIDEO liên quan: 101 điều cần biết về đột quỵ https://youtu.be/GGOIK2mnptU Viêm phổi ở trẻ em có dấu hiệu gì https://youtu.be/4tPgWEdaIYw 12 lời khuyên ăn uống lành mạnh mà vẫn siêu tiết kiệm https://youtu.be/JtUUkWPFB34 Vợ đưa bao cao su và bảo: Anh ra ngoài giải quyết https://youtu.be/nHKb7HKz3pM Vui chơi giúp trẻ thêm hiểu biết https://youtu.be/TU5jqMTfwHc Xét nghiệm máu: Một số đặc điểm tổng quan https://youtu.be/P-bDjLSB5Z4 5 phát hiện thêm hy vọng cho người ung thư https://youtu.be/GRPesry7xSs 4 phát minh giả sinh học làm thay đổi y học https://youtu.be/KvaHcKVr2rU 20 căn bệnh kỳ lạ, hiếm gặp nhất trên thế giới https://youtu.be/er-gc-I18Ro 4 cách sống hiện đại làm “biến đổi” bộ não con người https://youtu.be/h1v7b2ccJVI Xác định và xử trí điều trị bỏng https://youtu.be/0LahWfn3sEU Xông hơi: Phương pháp chữa bệnh độc đáo https://youtu.be/I5k_U97dwSE Xử trí khẩn cấp khi bị ngộ độc thuốc trừ sâu https://youtu.be/YJ4PRLvJLVQ Xét nghiệm dung nạp đường huyết https://youtu.be/SBem5VjFDNc Xét nghiệm chức năng gan https://youtu.be/SysIES1FmSg Xét nghiệm kháng nguyên và kháng thể https://youtu.be/y_Ofz4LhmrA Xạ hình Radionuclide Scan hoặc Isotope Scan https://youtu.be/MLeb9YIf_LA Xét nghiệm chức năng tuyến giáp https://youtu.be/sD2DMAuzvFA Vô sinh: Chứng bệnh thời hiện đại https://youtu.be/jAwqeRORF7k Vợ từ chối tôi, nhưng lại tự mình làm chuyện đó https://youtu.be/IaiQ421J2h4 Xông hơi sau khi tập thể thao có tốt không https://youtu.be/qAEsBpK_63I Vô sinh vì những thói quen không ngờ tới https://youtu.be/HMVsulRppDg Điều gì sẽ xảy ra khi cơ thể thiếu hụt vitamin D https://youtu.be/pjHQMZpiim0 10 siêu thực phẩm ngăn ngừa ung thư nên có trong thực đơn https://youtu.be/g03UDjgr4FQ 11 nguyên nhân gây đau nửa đầu mà bạn không ngờ tới https://youtu.be/vuBV1uuf0Cg 10 món ăn tốt cho người đau răng https://youtu.be/Tt1vnezq8Vc 10 nguyên tắc giáo dục giới tính cha mẹ cần dạy bé https://youtu.be/a8jr0u8v5ek Những món ăn có ích cho người bị viêm xoang mũi https://youtu.be/wQk0uImxIC4 “Chuyện ấy” ở phụ nữ tuổi xế chiều https://youtu.be/KWy7B0WgQaM Những loại đồ uống nên dùng, và không nên dùng trong ngày nắng nóng https://youtu.be/uUqEGDjdcf0 Làm đẹp da với collagen https://youtu.be/V_PR6rz6W3k 10 Cách làm sữa chua ngon tuyệt cú mèo, bạn không thể bỏ qua https://youtu.be/8BW_k24is6Q 10 lựa chọn đơn giản giúp khỏe mạnh và giảm cân nhanh https://youtu.be/Ko99ho0i1iY 10 cách để cân bằng nội tiết tố tự nhiên https://youtu.be/8xKxNRDlx6w Làm đẹp nhờ khoai lang tím https://youtu.be/0CPw_HPUOeg Những loài thủy quái có miệng đáng sợ nhất https://youtu.be/hvFlnFkv54Y 10 thói quen buổi sáng sẽ thay đổi cuộc sống của bạn https://youtu.be/ffqzmv9VaDA 10 thói quen ăn uống sai lầm sau thời kỳ mãn kinh https://youtu.be/TgCPBYMtoNc Ung thư đại trực tràng: Sát thủ diễn biến âm thầm https://youtu.be/idDxTElZ7ko Ung thư vú và thai nghén: Những điều cần biết https://youtu.be/3SpH05lGfCE “Chuyện ấy” với nỗi lo của cánh mày râu https://youtu.be/WTqxsd_yHP4 10 "tai nạn" các mẹ hay gặp khi cho con bú https://youtu.be/tNMRgcP-RzA Ung thư ở trẻ em: Sự khác biệt trong điều trị https://youtu.be/XTmykj6qEgM ---------- Một tác phẩm của Mạng Y Tế
ACE inhibitors (and ARBs) - Mechanism of action
 
07:27
ere's a short video detailing the mechanism of action of ACE inhibitors. It covers the mechanism behind the blood pressure lowering effects of ACEis and why they produce some of their side-effects.
Views: 3835 Matthew Wigley
NAGOYA HEART Study with Dr Toyoaki Murohara
 
07:54
http://www.theheart.org/podcast/video/trials-and-pis/nagoya-heart-study-with-dr-toyoaki-murohara.do Dr Toyoaki Murohara (Nagoya University School of Medicine, Nagoya, Japan) discusses the comparison of valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance (NAGOYA HEART Study) Filmed during ACC 2011 in New Orleans, LA on April 4.
Views: 194 theheartorg
Podcast Episode 003 - New drug approvals and 1st patient case
 
43:36
On episode 003 of the CCRx podcast, we discuss the new medications that have received FDA approval in December 2017. We also walk-through our first evidence-based patient case. The case handout can be found under episode 003 at www.corconsultrx.com/podcast along with hyperlinks to all the clinical trials that were discussed during the episode. Follow us on all social media platforms at @corconsultrx
Robert Lefkowitz (Duke University) Part 2: Beta-arrestins
 
51:39
https://www.ibiology.org/cell-biology/g-protein-coupled-receptors/#part-2 In part 2 of the lecture, recent discoveries about how Beta-arrestins not only desensitize the receptors but also mediate their endocytosis, as well as independent signaling pathways, are reviewed. Also covered is how these new discoveries provide a basis for designing novel classes of pharmacological agents which can promote signaling exclusively down either the G protein or Beta-arrestin mediated pathways, so called biased agonists. See more at www.ibiology.org
Views: 20664 iBiology
10819 en pioglitazone 45 mg qd
 
01:49
Pioglitazone 45mg QD
Views: 1029 CuescriptLLC
What Treatments for Diabetes Are Available?
 
01:48
http://ace-inhibitors.info If you have been put on beta blockers as part of your treatments for diabetes, then you are certainly not alone. Millions of Americans are taking beta blockers as a means to control the rhythms of their heart. When you have diabetes, you often have hypertension or high blood pressure, and beta blockers help to control this. In fact, these same drugs are used by people who need to be calm or have steady hands, such as musicians, surgeons or even professional billiards players!
Views: 108 aceinhibitors2
NNLM Resource Picks - Environmental Health & Toxicology (July 25, 2018)
 
01:03:49
To obtain MLA CE credit and offer feedback after viewing this recording, please take this evaluation: https://bit.ly/2C7T1zQ MLA CE credit is available for 6 months following each session of PNR Rendezvous. If you have questions, please email nnlm@uw.edu "Environmental Health & Toxicology Resources for the Public and Professionals" Recorded on July 25, 2018 Presenter: Shannon M. Jordan, MPH, Specialized Information Services, National Library of Medicine This presentation is to familiarize participants with environmental health and toxicology resources available online from the National Library of Medicine. Participants will also learn which resources to access and utilize for specific types of information related to pesticide exposure, toxic releases, household products, maternal/child health, occupational health and more. Class page: https://nnlm.gov/class/environmental-health-toxicology-resources-public-and-professionals/8409 The National Network of Libraries of Medicine is funded by the National Library of Medicine, National Institutes of Health, Department of Health and Human Services. Learn more at https://nnlm.gov
Is Garlic Good For You 7 Surprising Benefits Of Garlic For Optimal Health
 
01:10
Garlic does more than just invigorate your palate and ward off vampires; it’s also a smelly superfood health aid. The spice is a highly nutritious vegetable with very few calories, containing trace amounts of other nutrients that contribute to its universal status of a powerful, beneficial healer. The natural medicinal ingredient, both as a fresh plant and supplement, can strengthen immune function and boost overall well-being. Garlic’s delicious flavor and health benefits have led to a steady increase in demand. The average garlic consumption per capita per year is 2 pounds. A healthy adult can safely consume up to four cloves of garlic each day, according to the University of Maryland Medical Center, with each one weighing about a gram. The body-strengthening effects of this herb are thought to be due to its active ingredient allicin. This is what gives garlic its distinctive taste and smell. Whether you take your garlic powdered, salted, or minced or in supplement form, you can reap the surprising benefits of this multipurpose herb for optimal health. 1. TREATS ACNE This herb may not be found in acne products’ list of ingredients, but it can serve as a natural topical treatment to get rid of blemishes. Allicin, the organic compound in garlic, has the ability to stop the damaging effects of radicals and kill bacteria, according to a 2009 study published in the journal Angewandte Chemie. In its decomposed form — sulfenic acid — allicin produces a fast reaction with radicals, which makes it a valuable herb for treating acne scars, skin diseases, and allergies. 2. TREATS HAIR LOSS A head full of hair that smells like garlic could help in the treatment of hair loss. The herb’s extremely high sulfur content contains keratin, the protein hair is made of. This stimulates fortification and growth. A 2007 study published in the Indian Journal of Dermatology, Venerology and Leprology found the use of a garlic gel added to the therapeutic efficacy of topical betamethasone valerate for alopecia areata treatment can be effective to induce hair re-growth. 3. FIGHTS COMMON COLD Garlic’s allicin can serve as a health aid during times of illness. Rene Ficek, a registered dietician and a lead nutrition expert at Seattle Sutton's Healthy Eating in Illinois told Medical Daily in an email: “Garlic cloves contain a healthy dose of allicin, but you may still need a few cloves per day to feel the effects.” However, garlic supplementation can also be used to ward off viruses. A 2001 study published in the journal Advances In Therapy found a daily garlic supplement can reduce the number of colds by 63 percent compared to not taking supplements. Moreover, the average length of cold symptoms was also reduced to 70 percent, from five days in the control group to 1.5 days in garlic supplement group. These findings suggest the allicin-containing supplement has a protective effect against the common cold. 4. LOWERS BLOOD PRESSURE A garlic supplement a day may help keep your blood pressure at bay. Its active compounds can significantly reduce blood pressure comparable to the effects of prescribed drugs. Aged garlic extract between 600 to 1,500 milligrams (mg) was found to be just as effective as the drug Atenolol prescribed for hypertension in a 24-week period, according to a 2013 study published in the Pakistan Journal of Pharmaceutical Sciences. Garlic is believed to activate the production of the endothelium-derived relaxation factor, according to Ficek, due to the herb’s high amount of polysulfides — sulfur — containing molecules. This leads to smooth muscle relaxation and vasodilation (widening of blood vessels), following the relaxation of the smooth muscle in the vessel wall. Garlic supplements can achieve these effects efficiently without the bad breath compared to raw garlic. copy right : http://www.medicaldaily.com/
Views: 25 My Health